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RAF inhibitors have the unique property of transactivating RAS-dependent RAF dimers in most cells but
inhibit RAF/MEK/ERK signaling in cells expressing mutant BRAF, in which RAS activity is too low to support
this process. These drugs thus selectively inhibit ERK signaling in tumors with BRAFmutation. RAF inhibitors
have remarkable clinical activity in melanomas with BRAFV600E mutations; however, resistance invariably
develops. Three recent papers reveal that acquired resistance may be due to mechanisms that cause ERK
signaling to become insensitive to RAF inhibitors, or that reduce the dependence of the tumor on ERK
signaling through activation of other pathways.The discoveries that carcinogenesis depends on mutations that
dominantly activate mitogenic signaling and that established
tumors usually remain dependent on these pathways have led
to the idea that targeted inhibition of components of these
pathways would be especially effective for therapy. Recently,
examples in which this has been shown to be the case have
multiplied. Selective inhibitors of ABL, EGFR, HER2, KIT, and
ALK kinases have unprecedented clinical activity in tumors in
which their target is activated by a genetic event. However, resis-
tance to the effects of these drugs develops and, except for the
case of ABL inhibitors in chronic myelogenous leukemia, clinical
responses are usually temporary.
A recent illustration of this phenomenon is the remarkable
sensitivity of metastatic melanomas with BRAFV600E mutation
to RAF inhibitors developed by Plexxikon (PLX4032) and
GlaxoSmithKline (GSK2118436) (Flaherty et al., 2010; Kefford
et al., 2010). The RAS/RAF/MEK/ERK signaling pathway regu-
lates many key cellular processes, especially cell proliferation,
and is often dysregulated in human cancer. The pathway is nor-
mally regulated by growth factor receptors that, when activated,
cause RAS to adopt its active, GTP-bound state. RAS-GTP
binds in the membrane to multiple effector proteins including
the three members of the RAF kinase family (ARAF, BRAF,
and CRAF). Binding of these kinases to RAS-GTP leads to their
activation and the subsequent activation of a cascade of
kinases: RAF phosphorylates and activates its substrates
MEK1 and 2, which, in turn, phosphorylate and activate their
two substrates, ERK1 and ERK2. Activated ERK phosphorylates
a variety of nuclear and cytoplasmic substrates that mediate the
pleiotypic effects of the pathway (Young et al., 2009).
RAS/RAF/MEK/ERK signaling is hyperactivated in a high
percentage of tumors; this is frequently due to activating muta-
tions of the KRAS, NRAS, or BRAF genes. Activation of ERK
signaling is especially prevalent in malignant melanomas. More
than half of these tumors contain BRAF mutations, almost all of
which are V600E (Davies et al., 2002), and 15%–30% contain
mutations in NRAS (Sekulic et al., 2008). The prevalence of ERK
activation in tumors has led to the aggressive development of
RAF and MEK inhibitors as anticancer drugs. Experiments with
a selective allosteric inhibitor of the kinase activity of MEK showthat mutant BRAF melanoma cell lines and in vivo models are
especially dependent on MEK/ERK signaling (Solit et al., 2006).
However, in clinical trials, only a minority of patients with meta-
static melanoma with mutant BRAF undergo tumor regression
when treated with these drugs (Dummer et al., 2008; Infante
et al., 2010). In contrast, the two ATP-competitive RAF inhibitors
that have been tested in these patients have considerably more
antitumor activity. These drugs almost always cause tumor
regression in patients with this notoriously difficult to treat tumor.
However, tumors eventually regrow and progress in almost all
patients, with a median time to progression of approximately
seven months (Bollag et al., 2010; Flaherty et al., 2010). Three
recent papers (Johannessen et al., 2010; Nazarian et al., 2010;
Villanueva et al., 2010) reveal potential mechanisms of acquired
resistance to RAF inhibitors. Understanding these mechanisms
requires an understanding of the unusual biochemical effects of
RAF inhibitors that account for its clinical activity.
Inhibitors of other oncogenic kinases, including MEK, inhibit
their targets in all cells. The dose of these drugs is limited by the
degree of pathway inhibition that causes unacceptable toxicity,
and the therapeutic window, if any, is derived from hypersensi-
tivity of the tumor compared to normal tissue. Uniquely, RAF
inhibitors affect ERK signaling in a mutation-specific manner
(Hatzivassiliou et al., 2010; Heidorn et al., 2010; Hoeflich et al.,
2009; Joseph et al., 2010; Poulikakos et al., 2010) due to specific
features of RAF signaling (Figure 1). Activation of RAS promotes
the dimerization and membrane localization of members of the
RAF family. Binding of the RAF inhibitor to one member of
the RAF-dimer induces an allosteric change that transactivates
the other, unbound member of the dimer and activates the ERK
pathway. At high concentrations, the inhibitor binds both RAFs
in the dimer and results in pathway inhibition. RAS activity is
crucial for multiple aspects of RAF activation, including the
formation of dimers, and RAF induction by inhibitors requires
levels of RAS activity adequate to support formation of enough
RAF dimers capable of transactivation. In BRAFV600E mela-
nomas, RAS-GTP levels are insufficient and RAF inhibitors inhibit
RAF kinase activity and ERK signaling (Poulikakos et al., 2010).
Thus, inhibition of ERK signaling by RAF inhibitors is confined
to tumor cells and this reduces toxicity and allows more potentCancer Cell 19, January 18, 2011 ª2011 Elsevier Inc. 11
Figure 1. The Effect of RAF Inhibitors on ERK Signaling Depends on BRAF Status
In cells with wild-type BRAF (1), RAS promotes the formation of active RAF homo- and heterodimers (2). An ATP-competitive RAF inhibitor binds to RAF mole-
cules and inhibits them, while at the same time it induces transition to the active state of the kinase, as previously reported for other kinases (Cameron et al., 2009;
Okuzumi et al., 2009). However, in the case of RAF, a transition to the active state is transmitted to the inhibitor-free molecule in the dimer via direct interaction,
causing a marked increase in catalytic activity (3). At higher concentrations of inhibitor, the number of inhibitor-free molecule decreases and total cellular RAF
activity declines to lower than basal levels (4).
In cells with BRAFV600E and low RAS activity (5), BRAFV600E is the dominant MEK kinase and transactivation is precluded because RAFs do not form dimers
capable of transactivation: the RAF inhibitor effectively inhibits ERK signaling (6).
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MEK inhibitors, which suppress ERK signaling in all cells. This
model suggests that molecular lesions that enhance RAF dimer-
ization in tumor cells by activating RAS or by other means will
cause insensitivity of ERK signaling to the drug and thus tumor
resistance. The demonstrations in model systems that RAS
mutation (Poulikakos et al., 2010) or CRAF overexpression
(Montagut et al., 2008) cause resistance to RAF inhibitors are
consistent with this idea. The clinical relevance of this mecha-
nism has now been validated in at least one patient (Nazarian
et al., 2010). Cell lines resistant to the RAF inhibitor PLX4032
were derived from three melanoma cell lines that express
BRAFV600E. In one resistant line, MEK/ERK signaling was
insensitive to the drug. Analysis revealed that these cells con-
tained an activating mutation of NRAS and elevated RAS-GTP.
It was also shown that, in one patient treated with PLX4032,
development of resistance was associated with a new NRAS
mutation.
In the two other resistant cell lines, ERK signaling was at least
partially sensitive to the RAF inhibitor, suggesting that the12 Cancer Cell 19, January 18, 2011 ª2011 Elsevier Inc.phenotype is due to activation of other pathways that reduce
the dependence of the cell on BRAF signaling. Multiple receptor
tyrosine kinases were shown to be overexpressed in these cells,
only one of which, PDGFRb, was also hyperphosphorylated.
PDGFRb was upregulated in 4 out of 11 PLX4032-resistant
tumors from patients, suggesting that this mechanism may be
clinically relevant. Introduction of PDGFRb into BRAFV600E
melanomas created some degree of resistance, and proliferation
of resistant cells with elevated PDGFRb phosphorylation was in-
hibited by knockdown of the receptor. These data suggest that
PDGFR plays a role in mediating resistance, but the mechanism
underlying its overexpression is unknown. Activation of a growth
factor receptor could cause resistance by activating parallel
pathways that diminish dependence on ERK signaling or by
increasing RAS activity. Levels of RAS-GTP are higher in the
PDGFRb expressing clones than in the sensitive parent cells,
but not nearly at the levels induced by NRAS mutation. The
best argument for causation of drug resistance is reversal of
the phenotype in response to inhibition of the putative mecha-
nism. This is convincingly shown for the tumor cells that express
Figure 2. Potential Mechanisms of Acquired Resistance to RAF
Inhibitors
BRAFV600E melanoma tumors may acquire resistance to RAF inhibitors
through various mechanisms: RAS activation via RAS mutation (1) or receptor
tyrosine kinase (RTK) activation (2, 3) promote RAF dimerization and subse-
quently compromise suppression of ERK signaling by RAF inhibitors. Activa-
tion of another MEK kinase, COT (4) would render ERK signaling refractory
to RAF inhibition. RTK activation (2, 3) will in addition provide partial MEK-inde-
pendence by activating other survival pathways.
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sensitized these tumors to RAF inhibition (Nazarian et al., 2010).
The PDGFRb cells were insensitive to the PDGFR inhibitor Ima-
tinib; it would be useful to test the effects of combining Imatinib
and the RAF inhibitor. If PDGFRb is the dominant mechanism of
resistance, resistant cells should be sensitive to this combina-
tion.
Villanueva et al. describe a similar approach: resistant cell lines
were selected in the context of chronic treatment with another
RAF inhibitor (Villanueva et al., 2010). In these cells, ERK
signaling was insensitive to the RAF inhibitor or to knockdown
of BRAF, CRAF, or ARAF expression individually, but sensitive
to the RAF inhibitor in cells in which ARAF and CRAF expression
were knocked down as well. They concluded that ERK signaling
was still under RAF control, but, in the presence of inhibitors,
dependency on mutant BRAF dynamically switched to depen-
dence on other, wild-type isoforms. The underlying mechanism
is unknown, but it is tempting to speculate that this reflects
drug-induced transactivation of RAF isoforms in a cell in which
resistance is mediated by upstream or mutational activation of
RAS or to changes in RAF isoform expression that favor dimer-
ization.
This study also associated resistance with activation of
receptor tyrosine kinases, particularly IGF1 receptor (IGF1R)
and demonstrated decreased viability of melanomas exposed
to IGF1R inhibitors. These results must be interpreted with
some caution, as the IGF1R inhibitors used are not very selec-
tive. These inhibitors did suppress AKT activation and they
enhanced cell death when given in combination with MEK inhib-
itors. Villanueva et al. (2010) report that in one out of five cases of
melanomas that relapsed while being treated with PLX4032, the
resistant tumor expressed IGF1R and phosphorylated AKT, but
the original tumor did not. Homozygous loss of PTEN together
with phosphorylated AKT was noted to be associated with
acquisition of resistance in another tumor. Analysis of more clin-
ical samples will be required to assess the potential importance
of this mechanism for conferring resistance.
Recent work suggests that in tumors with dysregulation of
both PI3K and ERK signaling, both pathways must be inhibited
to efficiently inhibit growth. These include tumors with RAS
mutation, alone or in combination with PI3K mutation, or tumors
in which EGFR activation or RAF mutation coexist with PTEN
loss (Engelman et al., 2008). In these tumors, the two pathways
converge on downstream targets that regulate cell survival
directly (BAD) or via regulation of cap-dependent translation
(4EBPs)(She et al., 2010). In mutant BRAFmelanoma, the effects
of inhibition of ERK signaling by MEK inhibitors on cell growth
and survival have been shown to correlate inversely with basal
or post-treatment level of AKT activation (Gopal et al., 2010). It
is quite plausible that activation of IGF1R and PDGFRb contrib-
utes to RAF inhibitor resistance by activating PI3K signaling.
However, since PTEN has been found to be deleted in 25% of
melanoma cell lines with mutant BRAF and only approximately
10%ofmelanomaswithmutant BRAF exhibit de novo resistance
to RAF inhibitors, activation of AKT signaling may not confer
resistance by itself.
In a third paper, Johannessen and colleagues used a novel
technique to identify mechanisms of resistance (Johannessen
et al., 2010). They introduced a cDNA library encoding 75%of annotated human kinases into a melanoma cell line with
mutant BRAF and identified nine kinases that conferred resis-
tance. Two of these, CRAF and the MAP kinase kinase Tpl2/
COT (encoded by MAP3K8), were analyzed further and shown
to cause ERK signaling to become insensitive to RAF inhibition.
This is especially important because for the first time, it suggests
the possibility that activation of alternative kinases that phos-
phorylate MEK can replace the requirement for RAF and main-
tain ERK signaling. This may be mechanistically analogous to
acquisition of EGFR inhibitor resistance by activation of another
tyrosine kinase, Met (Engelman et al., 2007).
COT not only activates ERK signaling in a RAF-independent
manner, but its expression is also inversely correlated with that
of BRAFV600E. The inference is that mutant BRAF activation
downregulates COT expression and that the aberrant expression
of COT causes resistance to RAF inhibitors. COT overexpression
represents another mechanism for resistance: lesions that cause
the mutant BRAF-independent activation of ERK signaling. Two
of 38 BRAF mutant cell lines with chromosomal copy number
gains that span the MAP3K8 locus were identified. These cells
expressed COT and were resistant to RAF inhibitors. ERK
signaling in these cell lines was insensitive to RAF inhibition
but inhibited by a COT inhibitor or COT knockdown. Thus, there
is some preliminary evidence for a mechanism (gene amplifica-
tion) responsible for abnormal COT expression in cells with
mutant BRAF. COT expression was detected in two out of three
human melanomas with acquired resistance to RAF inhibitor,
suggesting that this mechanism may be clinically relevant.
Thus, multiple mechanisms for resistance to RAF inhibitors
have now been identified (Figure 2). Some lead to insen-
sitivity of RAF kinase to the inhibitor: NRAS mutation, CRAFCancer Cell 19, January 18, 2011 ª2011 Elsevier Inc. 13
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RAFs. The first two are consistent with the mechanism of
action of the RAF inhibitor, from which it can be inferred that
anything which increases RAF dimerization and transactivation
will confer this pattern of resistance. Gatekeeper mutations
have been shown to be the most common cause of resistance
to ABL, EGFR, and KIT inhibitors. Gatekeeper mutations of
BRAF that are resistant to inhibition by RAF inhibitors have
been described (Whittaker et al., 2010), but, curiously, they
have not been found in tumors with acquired resistance to
these drugs. The reason for this is unknown; it could reflect
decreased signaling or transforming function of these mutants.
All of these lesions cause resistance to RAF inhibitors, but the
tumor retains dependence on RAF activation. Another mecha-
nism, COT activation, is different; it causes RAF-independent
ERK kinase signaling. Thus, as is true for other tumors, it is
rare for resistant tumors to become independent of the
signaling pathway activated by the driver mutation.
The last mechanism is the exception; it involves activation of
receptors such as PDGFRb and IGF1R that activate multiple
signaling pathways that could reduce the ERK dependence of
the cell but, also, by increasing RAS-GTP, attenuates the effects
of the RAF inhibitor on ERK signaling. It has been suggested that
almost complete (> 80%) inhibition of ERK signaling is required
for tumor responses to RAF inhibition; moderate inhibition is
ineffective (Bollag et al., 2010). These data suggest that even
a modest decrease in the effectiveness of inhibition of ERK
signaling by the drug could cause resistance. This will be difficult
to assess in tumor samples without more accurate quantitative
methods for assessing inhibition of ERK output. In the case of
tumors with coexistent RAS mutations and PI3K pathway muta-
tions, tumors are sensitive to combined inhibition of MEK and
PI3K signaling. In BRAF mutant tumors, overexpression of
receptor tyrosine kinases or mutations in RAS will both activate
PI3K and other parallel pathways and also elevate RAS-GTP,
thus attenuating the ability of RAF inhibitors to inhibit ERK
signaling.
One may ask why such a profusion of mechanisms for resis-
tance to RAF inhibitors have been defined and why mutations
in the target, the prevalent mechanism of resistance to inhibitors
of other kinases, have not been identified. It may have to do with
themechanism underlying the unique effectiveness of RAF inhib-
itors. In most cells, ERK signaling is insensitive to these RAF
inhibitors, so resistance may result from any lesion that leads
to modest levels of RAS signaling. It also may be worth
mentioning that each of these papers reports distinct mecha-
nisms of resistance in different melanoma cell lines. It may be
that different genetic backgrounds and complement of somatic
mutations in each tumor predispose to selection of different
mechanisms of resistance. We do have to acknowledge that
these are recent discoveries and the relative importance of these
mechanisms for resistance in patients has not yet been defined.
The underlying molecular lesion responsible for the resistance
mechanisms reported in these papers is clear only for the case
of NRAS mutation and acquisition of this mutation has been
identified in only one patient. Dynamic switching from BRAF to
wild-type RAF dependence, as hypothesized in Villanueva
et al. (2010), and feedback reactivation of COT expression after
ERK pathway inhibition should occur rapidly in all mutant BRAF14 Cancer Cell 19, January 18, 2011 ª2011 Elsevier Inc.tumors exposed to drug. This is not consistent with the clinical
data that most tumors respond for months to RAF inhibitors,
so these mechanisms must require selection of molecular
lesions responsible for the biochemical effects. COT overex-
pression may be due to gene amplification in some cases; this
will require further proof. Neither the Villanueva et al. (2010) nor
the Nazarian et al. (2010) papers identify the underlying lesion
responsible for RAF switching or for IGF1R or PDGFRb overex-
pression. The finding that multiple kinases are overexpressed
and the insensitivity of these tumors to the PDGFR inhibitor
Imatinib alone (Nazarian et al., 2010) suggests that the primary
lesion creating resistance could be upstream of PDGFR and
have effects on other signaling pathways as well. There is clearly
a need to obtain much more tumor material, preferably sensitive
and resistant pairs, to determine which of these mechanisms
contribute significantly to clinical resistance.
The most important consequence of identifying relevant
resistance mechanisms will be the development of effective
therapeutic strategies for their reversal. PDGFRb and IGF1R
inhibitors are already in clinical use and COT inhibitors are in
development. Resistance mediated by RAF inhibitor-refractory
ERK signaling may be reversed by combined therapy with RAF
and MEK inhibitors. The excitement generated by the initial
unprecedented clinical activity of RAF inhibitors in melanoma
has now been tempered by the realization that the tumor
responses are temporary. These three papers and other recent
studies (Corcoran et al., 2010; Paraiso et al., 2010) suggest
a path for the development of even more effective therapies for
these patients.
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